Self-reported data from a patient registry is a valuable resource for researchers

By Vanessa Rangel Miller, Invitae

Invitae’s Patient Insights Networks (PINs) are web-based patient opt-in registries that can provide reliable data for researchers, particularly for rare diseases. Disease registries are not a new concept in clinical research. Investigators have long used registries to aid in hypothesis generation, data mining, and clinical trial recruitment, among other utilities. Yet there remains some skepticism by…

Read More

Are you missing patients who need genetic testing?

It’s national hereditary breast & ovarian cancer week. Are you ensuring that all patients who qualify for genetic testing get it? An estimated 1.2 to 1.3 million women in the US with breast or ovarian cancer who qualified for genetic testing failed to receive it1 More than 70% of patients with breast cancer and 80%…

Read More

Need guidance on integrating cardiogenetics into your practice?

Wondering how to best utilize genetic testing in your cardiology practice? Professional societies have long recommended genetic testing in the care of individuals and families with inherited cardiovascular diseases.1-5 Recognizing the obstacles to integrating genetic testing into every cardiology practice, recently published articles highlight why, when, and how to offer genetic testing appropriately and effectively in your practice.6,7…

Read More

Food Allergy Research & Education (FARE) launches PIN

Food Allergy Research & Education (FARE) has launched the FARE Patient Registry, which leverages Invitae’s Patient Insights Network (PIN) platform to enable permission-based sharing of patient data to advance the understanding and treatment of inherited health conditions. The FARE Patient Registry amplifies patients’ voices and insight to accelerate research to uncover the causes of food…

Read More

OlympiAD trial: BRCA-positive mBC outcomes improved with PARP inhibitor

Targeted therapies are few for patients with HER2-negative breast cancer. A phase III trial presented at the ASCO Annual Meeting1 described a way to identify potential therapeutic benefit from a PARP inhibitor: BRCA status. The OlympiAD trial demonstrated that the PARP inhibitor olaparib yielded improved survival over chemotherapy for HER2-negative metastatic breast cancer (mBC) patients…

Read More

Leading with quality: Variant classification

At Invitae, we believe there’s a new gold standard today, one that includes both high-quality testing and a dedication to improving medicine by sharing data and best practices. We recently published our approach to variant classification in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG). The paper…

Read More

Invitae’s Gene of the Week educational series

The field of genetics is constantly evolving as new data emerges linking genes and disease. As your partner in genetic testing, we’re working to provide the most up-to-date resources to support your practice. If you’re looking to learn about some not-so-common genes or searching for a database of information to support your clinic notes, Invitae’s…

Read More